Cargando…
Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB
BACKGROUND: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on...
Autores principales: | Engelbrechtsen, L., Lundgren, J., Wewer Albrechtsen, N. J., Mahendran, Y., Iepsen, E. W., Finocchietto, P., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T., Torekov, S. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729494/ https://www.ncbi.nlm.nih.gov/pubmed/29259801 http://dx.doi.org/10.1002/osp4.133 |
Ejemplares similares
-
Proteomics reveals the effects of sustained weight loss on the human plasma proteome
por: Geyer, Philipp E, et al.
Publicado: (2016) -
SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023) -
Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
por: Iepsen, E W, et al.
Publicado: (2015) -
Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics
por: Björnson, E., et al.
Publicado: (2019) -
Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded K(v)11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia
por: Hyltén-Cavallius, Louise, et al.
Publicado: (2017)